PRECLINICAL. NOT IN HUMAN TRIALS

SLU-PP-332

An "exercise mimetic" small molecule discovered at Saint Louis University in 2023. Animal data is striking. Human evidence does not yet exist. The hype is running well ahead of the science.

The 30-second read

SLU-PP-332 is a small molecule (technically not a peptide) discovered by Bahaa Elgendy's lab at Saint Louis University and reported in 2023. It activates ERR receptors (estrogen-related receptors), nuclear receptors that turn up the genes responsible for mitochondrial energy production. In mice, treatment with SLU-PP-332 produced effects that look strikingly like exercise: better endurance, more fat-burning, weight loss in obese mice, and improved metabolic markers, all without the animals actually exercising. That's why it's been called "exercise in a pill." It is not in human trials yet. It is preclinical research. The "peptide-research" community has started discussing it; supply is sketchy and unreliable, and human safety is completely uncharacterized.

Why this is on people's radar

"Exercise in a pill" is a phrase that's been promised many times in pharmacology and almost never delivered. SLU-PP-332 caused a stir in 2023 because the animal data, published from Bahaa Elgendy's lab at Saint Louis University, looked unusually clean. Treated mice showed better treadmill endurance, lost more fat on a high-fat diet, and developed the muscle-fiber and mitochondrial changes typically associated with regular exercise, without exercising. The mechanism is unusual: SLU-PP-332 activates all three ERR receptors (estrogen-related receptors α, β, and γ), nuclear receptors that turn up the master metabolic and mitochondrial gene programs.

Two reasons the conversation took off. First, the longevity and metabolic-medicine worlds have been hunting for a real exercise mimetic for decades. Compounds like AICAR have been tried but didn't translate to humans well. SLU-PP-332's mouse data was unusually striking. Second, the obesity-drug landscape has been dominated by GLP-1s, drugs that work by reducing appetite. SLU-PP-332 works on a different axis (energy expenditure and fat-burning rather than food intake), which raised the prospect of a drug that could complement or stack with the GLP-1 class.

The honest backdrop: this is preclinical research. As of 2026, SLU-PP-332 has not entered human clinical trials. Animal studies are reported to be promising but limited in scope. The "exercise mimetic" framing, repeated everywhere from longevity podcasts to mainstream press, runs ahead of what the data actually supports. And the appearance of "SLU-PP-332" in research-peptide channels is genuinely premature for a compound that hasn't been characterized for human safety.

What people are usually trying to do with it

People reading about SLU-PP-332 are usually drawn to the same ideas:

  • The exercise-mimetic promise, getting metabolic benefits without the gym time
  • Fat loss through energy expenditure rather than appetite reduction
  • Supporting mitochondrial function and exercise capacity as they age
  • A potential complement to GLP-1 weight-loss medications
  • Following the longevity research at the bleeding edge

What the science actually shows

All of it is preclinical, mostly from one research group. Plain-English summary:

Mouse exercise-mimetic effects

The original paper reported that SLU-PP-332 treatment in mice produced increased endurance on treadmill testing, more fat-burning during exercise, shifts toward fatigue-resistant muscle fiber types, and resistance to diet-induced obesity. Striking results in the model.1

Pan-ERR receptor agonism

Mechanism: SLU-PP-332 activates all three ERR receptor subtypes (α, β, γ). The ERR family controls mitochondrial gene expression, fatty acid oxidation, and oxidative metabolism, a network central to exercise adaptation.2

Heart and metabolic effects in animal models

Subsequent work has reported cardiac and broader metabolic effects in animal models, including improvements in markers relevant to heart failure with preserved ejection fraction and metabolic syndrome.3

What hasn't been demonstrated

Any effect in humans. There are no Phase 1 trials registered as of 2026. No human pharmacokinetic studies, no human safety data, no human dosing characterization. The leap from "mouse exercise mimetic" to anything you'd take seriously in humans requires a clinical-development pipeline that hasn't started.

Replication and independent confirmation

The original findings come from one academic group. Independent replication of the striking exercise-mimetic effects in additional labs, in additional species, has not yet been published at scale.

The honest read

What's solid:

The original mouse data is real and striking. The mechanism. ERR receptor agonism driving mitochondrial gene programs, is biologically coherent and consistent with the observed effects. The discovery is a meaningful scientific contribution.

What's still completely unknown:

Anything about human use. Human pharmacokinetics, human safety, human efficacy, human dose-response. The compound has not entered Phase 1 trials. Long-term effects of pan-ERR activation in humans are unknown. Whether the mouse-model effects translate at all is genuinely an open question.

What's hyped beyond the evidence:

Treating SLU-PP-332 as something to take. It's preclinical research. The "exercise in a pill" framing has appeared in mainstream press and longevity podcasts as if the compound were close to use; it isn't. Research-peptide-channel availability of "SLU-PP-332" is operating well outside the normal scientific path for a compound at this stage. Anyone using it is participating in a personal experiment with unknown safety and unknown sourcing, closer to N-of-1 self-experimentation than evidence-based use.

Things to know if you're looking into it

  • It's preclinical. No Phase 1 trials. No human safety data. No human dosing. The most important fact about SLU-PP-332 is that the clinical-development work hasn't been done.
  • It's not technically a peptide. SLU-PP-332 is a small molecule (a synthetic compound), not a peptide. Included on this site because it shows up in the same metabolic and longevity conversations.
  • Sourcing is genuinely unreliable. Compounds at this stage shouldn't be in research-peptide channels. Anything sold as "SLU-PP-332" right now has no manufacturing oversight, no quality control, and no relationship to the published research material.
  • Mechanism is broad, not selective. Pan-ERR activation hits a lot of biology at once. ERR-α, β, and γ have different tissue distributions and roles. Activating all three has unknown long-term consequences.
  • Theoretical concerns: ERR activation drives mitochondrial biogenesis but also has effects on tumor metabolism, cardiac function, and reproductive biology. None of these have been tested in human safety contexts.
  • Healthcare provider involvement: there isn't really a clinician scenario for SLU-PP-332 use right now. The compound is research-only and not yet ready for clinical use.
  • Specific mechanism detail and references: in the "Want to go deeper?" section below.

What people often ask

Is SLU-PP-332 actually "exercise in a pill"?

In mice, it produces effects that look exercise-like. In humans, no one knows yet, the compound hasn't been tested in humans. The "exercise in a pill" phrase makes for good headlines and bad expectations.

Could I take it now?

It's available through research-peptide-style channels but it shouldn't be. The compound has not gone through human safety testing. Anyone taking it now is doing personal experimentation with no manufacturing oversight, no clinical guidance, and no idea how it will behave in a human body. This isn't even the situation with most peptides discussed on this site, where there's at least animal-and-some-human data plus a longer history of community use.

How would it be different from a GLP-1?

Different mechanism entirely. GLP-1 drugs (semaglutide, tirzepatide) reduce food intake by acting on appetite-related receptors. SLU-PP-332 (in mice) increases energy expenditure and fat-burning at the cellular level. If both mechanisms turned out to work in humans, they could in theory be complementary, but that's a long way from "in theory" given the clinical-development gap.

Is it safe?

No human safety data exists. The animal data hasn't reported red flags but animal toxicology is a different question from comprehensive human safety. ERR activation has theoretical implications for tumor biology, cardiac function, and reproductive systems that haven't been tested in humans.

When will it be in clinical trials?

As of May 2026, no Phase 1 trials are registered on ClinicalTrials.gov for SLU-PP-332 specifically. The Saint Louis University team and partners may be pursuing development, but it isn't public-facing yet.

Will it actually replace exercise?

Even if it works as well in humans as in mice, a big if, there's a lot more to the benefits of exercise than the metabolic-and-mitochondrial signal. Cardiovascular conditioning, muscle and bone loading, mood effects, social and motivational benefits aren't captured by a pill that activates ERR receptors. The framing as a replacement is overstating what any single mechanism can deliver.

Why is it on the radar at all if it's preclinical?

The original mouse data was unusually striking, the longevity world had been waiting for a real exercise mimetic, and the news cycle picked up on it. Preclinical data with strong mechanistic logic and a charismatic framing can travel a long way before any clinical work happens, and SLU-PP-332 is a vivid example of that.

FDA and regulatory status

Status as of May 5, 2026: Preclinical. Not FDA-approved. Not in human clinical trials. No Phase 1 trials registered on ClinicalTrials.gov as of this date. Not on the FDA Category 2 list (the compound isn't even at the stage where Category 2 questions apply). Status updates land here when they happen.

Want to go deeper? ERR receptor biology, mechanism detail, the original animal studies, theoretical concerns, and references.

Background and discovery

SLU-PP-332 is a synthetic small molecule (not a peptide) reported in 2023 by Bahaa Elgendy and colleagues at Saint Louis University. The compound was identified through medicinal chemistry work targeting the estrogen-related receptor (ERR) family of nuclear receptors. The "SLU" prefix marks the compound's institutional origin (Saint Louis University); "PP" stands for the chemical class; "332" is the compound number. It is not currently licensed for clinical development by a pharmaceutical company.

Mechanism of action

ERR receptor activation

SLU-PP-332 acts as a pan-agonist of the three ERR receptor subtypes. ERR-α, ERR-β, and ERR-γ. ERRs are nuclear receptors that, despite their name, do not bind estrogen. They function as constitutive activators of gene programs related to mitochondrial biogenesis, oxidative phosphorylation, fatty acid oxidation, and energy metabolism.

Mitochondrial and metabolic gene upregulation

ERR activation drives transcription of nuclear-encoded mitochondrial genes, increasing the cellular capacity for oxidative metabolism. This is the same set of gene programs that exercise activates through PGC-1α and related coactivators, which is why ERR agonism produces an "exercise mimetic" phenotype.

Fatty acid oxidation and metabolic flexibility

In animal models, SLU-PP-332 increases the body's preference for burning fat over carbohydrate during rest and exercise, a marker of "metabolic flexibility" associated with metabolic health.

Why ERRs and not PPARs?

PPAR agonists (the family that includes thiazolidinediones for diabetes) activate overlapping metabolic gene programs but are limited by side effects in clinical development. ERRs are upstream of similar metabolic programs and the hope behind compounds like SLU-PP-332 is that ERR activation might capture the metabolic benefits with a different side-effect profile.

Animal studies and clinical-development status

Original 2023 paper (Elgendy lab): Mice given SLU-PP-332 showed improved exercise endurance on treadmill testing, increased fat oxidation, and resistance to diet-induced obesity. Muscle biopsies showed shifts toward fatigue-resistant fiber types and increased mitochondrial content.

Subsequent work: Additional animal studies have reported effects on cardiac function in heart-failure models and on broader metabolic markers in models of metabolic syndrome.

Clinical development: No Phase 1 trials registered as of May 2026. No major pharmaceutical company has announced development. Whether the compound advances to human studies depends on partnerships, additional preclinical work, and regulatory engagement that hasn't been publicly disclosed.

Theoretical safety concerns

The pan-ERR mechanism activates a broad set of metabolic and mitochondrial gene programs. Areas of theoretical concern that haven't been characterized in human contexts:

  • Tumor metabolism: ERR-α in particular has been linked to aggressive cancer phenotypes in some contexts. Activation could theoretically influence tumor progression in occult or undiagnosed malignancy.
  • Cardiac biology: ERR-γ is highly expressed in cardiac tissue and modulates heart energy metabolism. Long-term pan-ERR activation has unknown chronic effects on cardiac function.
  • Reproductive biology: ERR-β has roles in reproduction and embryonic development. Activation in reproductive-age individuals has unknown implications.
  • Off-target effects: a small molecule active across three nuclear receptors typically has off-target activity at related receptors that hasn't been fully characterized.

None of these concerns is a known clinical issue, they're theoretical because the human data needed to characterize them doesn't exist.

References

  1. Billon C, Sitaula S, Banerjee S, et al. (2023). "Synthetic ERRα/β/γ agonist induces an ERRα-dependent acute aerobic exercise response and enhances exercise capacity." ACS Chem Biol, 18(3), 756–771. PubMed
  2. Tripathi M, Yen PM, Singh BK. (2020). "Estrogen-related receptor alpha: an under-appreciated potential target for the treatment of metabolic diseases." Int J Mol Sci, 21(5), 1645. PubMed
  3. Subsequent SLU-PP-332 cardiac and metabolic studies (2024–2025). Various journals; track via PubMed for the latest.
  4. ClinicalTrials.gov search for "SLU-PP-332": no registered trials as of May 2026. ClinicalTrials.gov
For educational and research purposes only. This is not medical advice. SLU-PP-332 is preclinical and has not entered human clinical trials as of May 2026. Anything sold as "SLU-PP-332" through research-peptide channels operates outside any oversight or quality control. Consult a licensed healthcare provider before considering any peptide or compound. PeptideLibraryHub is independent and does not sell peptides or accept money from anyone who does.